Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Investing Activities: 2019-2025

Historic Cash from Investing Activities for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $4.5 million.

  • BridgeBio Pharma's Cash from Investing Activities fell 88.32% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.4 million, marking a year-over-year decrease of 120.91%. This contributed to the annual value of $60.8 million for FY2024, which is 12.49% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Cash from Investing Activities stood at $4.5 million, which was up 134.33% from -$13.0 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Cash from Investing Activities ranged from a high of $149.7 million in Q2 2022 and a low of -$282.1 million during Q1 2021.
  • Over the past 3 years, BridgeBio Pharma's median Cash from Investing Activities value was $4.1 million (recorded in 2023), while the average stood at $9.5 million.
  • Per our database at Business Quant, BridgeBio Pharma's Cash from Investing Activities skyrocketed by 32,586.03% in 2022 and then tumbled by 4,804.55% in 2024.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Cash from Investing Activities stood at $21.8 million in 2021, then fell by 17.59% to $18.0 million in 2022, then tumbled by 100.37% to -$66,000 in 2023, then crashed by 4,804.55% to -$3.2 million in 2024, then slumped by 88.32% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, -$13.0 million for Q2 2025, and -$1.6 million during Q1 2025.